ATLyphe
ATLyphe was founded in 2023 and is headquartered in Zurich, Switzerland.
- Headquarters
- Zurich
- Founded
- 2023
- Business Model
- B2B
- Website
- atlyphe.com
About
ATLyphe AG is a Swiss biotech company, spun out of ETH Zurich and the University of Zurich, developing bispecific T cell engager therapies to improve outcomes for acute myeloid leukemia (AML) patients. Its lead candidate, ALY117, is designed as a safer, more precise conditioning agent for hematopoietic stem cell transplantation (HSCT), removing residual leukemic cells while preparing patients for transplant. The company aims to unlock the full curative potential of HSCT, which today is the only curative option for AML but often falls short due to the toxicity of existing conditioning regimens.
Summary
ATLyphe is a Biotech company based in Zurich, Switzerland, founded in 2023.
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/atlyphe"><img src="https://indexed.vc/api/badge/company/atlyphe" alt="ATLyphe on Indexed.vc" width="260" height="76" /></a>